Physician profile
Eric E Coris
NPI 1114955770
$395.51
in general payments reported to CMS, 2019-2025
11 companies · $235 in 2025
The $235 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $161 · 2025: $235.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $396.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $395.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $119.53 | 2024-2025 | Krystexxa, Repatha, Repatha |
| Sanofi-Aventis U.S. LLC | $45.97 | 2025 | |
| Novo Nordisk INC | $44.73 | 2024-2025 | Ozempic, Rybelsus |
| Recor Medical INC | $40.08 | 2024 | Paradise Renal Denervation System |
| Glaxosmithkline, LLC. | $31.64 | 2025 | |
| Dynavax Technologies Corporation | $28.96 | 2025 | Heplisav-B |
| Bayer Healthcare Pharmaceuticals INC. | $21.26 | 2024 | |
| Boston Scientific Corporation | $17.35 | 2025 | General - Pain Management |
| Exact Sciences Corporation | $16.34 | 2025 | |
| Astrazeneca Pharmaceuticals Lp | $15.04 | 2025 | Airsupra |
| Lilly USA, LLC | $14.61 | 2024 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Coris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.